Defective base excision repair in the response to DNA damaging agents in triple negative breast cancer

English version

Autoři: Kevin J. Lee ^aff001; Cortt G. Piett ^aff003; Joel F. Andrews ^aff001; Elise Mann ^aff002; Zachary D. Nagel ^aff003; Natalie R. Gassman ^aff001
Působiště autorů: Mitchell Cancer Institute, University of South Alabama, Mobile, AL, United States of America ^aff001; University of South Alabama College of Medicine, Mobile, AL, United States of America ^aff002; Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, United States of America ^aff003
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0223725

Souhrn

DNA repair defects have been increasingly focused on as therapeutic targets. In hormone-positive breast cancer, XRCC1-deficient tumors have been identified and proposed as targets for combination therapies that damage DNA and inhibit DNA repair pathways. XRCC1 is a scaffold protein that functions in base excision repair (BER) by mediating essential interactions between DNA glycosylases, AP endonuclease, poly(ADP-ribose) polymerase 1, DNA polymerase β (POL β), and DNA ligases. Loss of XRCC1 confers BER defects and hypersensitivity to DNA damaging agents. BER defects have not been evaluated in triple negative breast cancers (TNBC), for which new therapeutic targets and therapies are needed. To evaluate the potential of XRCC1 as an indicator of BER defects in TNBC, we examined XRCC1 expression in the TCGA database and its expression and localization in TNBC cell lines. The TCGA database revealed high XRCC1 expression in TNBC tumors and TNBC cell lines show variable, but mostly high expression of XRCC1. XRCC1 localized outside of the nucleus in some TNBC cell lines, altering their ability to repair base lesions and single-strand breaks. Subcellular localization of POL β also varied and did not correlate with XRCC1 localization. Basal levels of DNA damage correlated with observed changes in XRCC1 expression, localization, and measure repair capacity. The results confirmed that XRCC1 expression changes indicate DNA repair capacity changes but emphasize that basal DNA damage levels along with protein localization are better indicators of DNA repair defects. Given the observed over-expression of XRCC1 in TNBC preclinical models and tumors, XRCC1 expression levels should be assessed when evaluating treatment responses of TNBC preclinical model cells.

Klíčová slova:

Base excision repair – Breast cancer – DNA damage – DNA repair – Immunoblotting – Immunofluorescence – Transfection – Preclinical models

Zdroje

1. Li SX, Sjolund A, Harris L, Sweasy JB. DNA repair and personalized breast cancer therapy. Environ Mol Mutagen. 2010;51(8–9):897–908. doi: 10.1002/em.20606 20872853; PubMed Central PMCID: PMC2962983.

2. Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, et al. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ Breast Cancer. 2017;3:31. doi: 10.1038/s41523-017-0025-7 28948212; PubMed Central PMCID: PMC5572474.

3. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet. 2006;38(9):1043–8. doi: 10.1038/ng1861 16921376.

4. Karahalil B, Bohr VA, Wilson DM, 3rd. Impact of DNA polymorphisms in key DNA base excision repair proteins on cancer risk. Hum Exp Toxicol. 2012;31(10):981–1005. doi: 10.1177/0960327112444476 23023028; PubMed Central PMCID: PMC4586256.

5. Abdel-Fatah TM, Russell R, Agarwal D, Moseley P, Abayomi MA, Perry C, et al. DNA polymerase beta deficiency is linked to aggressive breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts. Mol Oncol. 2014;8(3):520–32. doi: 10.1016/j.molonc.2014.01.001 24462520; PubMed Central PMCID: PMC5528629.

6. Jiang J, Zhang X, Yang H, Wang W. Polymorphisms of DNA repair genes: ADPRT, XRCC1, and XPD and cancer risk in genetic epidemiology. Methods Mol Biol. 2009;471:305–33. doi: 10.1007/978-1-59745-416-2_16 19109787.

7. Patrono C, Sterpone S, Testa A, Cozzi R. Polymorphisms in base excision repair genes: Breast cancer risk and individual radiosensitivity. World J Clin Oncol. 2014;5(5):874–82. doi: 10.5306/wjco.v5.i5.874 25493225; PubMed Central PMCID: PMC4259949.

8. Caldecott KW. DNA single-strand break repair. Experimental cell research. 2014;329(1):2–8. doi: 10.1016/j.yexcr.2014.08.027 25176342.

9. Wilson SH, Kunkel TA. Passing the baton in base excision repair. Nat Struct Biol. 2000;7(3):176–8. doi: 10.1038/73260 10700268.

10. Audebert M, Salles B, Calsou P. Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem. 2004;279(53):55117–26. doi: 10.1074/jbc.M404524200 15498778.

11. Frit P, Barboule N, Yuan Y, Gomez D, Calsou P. Alternative end-joining pathway(s): bricolage at DNA breaks. DNA Repair (Amst). 2014;17:81–97. doi: 10.1016/j.dnarep.2014.02.007 24613763.

12. Mladenov E, Iliakis G. Induction and repair of DNA double strand breaks: the increasing spectrum of non-homologous end joining pathways. Mutat Res. 2011;711(1–2):61–72. doi: 10.1016/j.mrfmmm.2011.02.005 21329706.

13. Moser J, Kool H, Giakzidis I, Caldecott K, Mullenders LH, Fousteri MI. Sealing of chromosomal DNA nicks during nucleotide excision repair requires XRCC1 and DNA ligase III alpha in a cell-cycle-specific manner. Molecular cell. 2007;27(2):311–23. doi: 10.1016/j.molcel.2007.06.014 17643379.

14. Narciso L, Fortini P, Pajalunga D, Franchitto A, Liu P, Degan P, et al. Terminally differentiated muscle cells are defective in base excision DNA repair and hypersensitive to oxygen injury. Proc Natl Acad Sci U S A. 2007;104(43):17010–5. doi: 10.1073/pnas.0701743104 17940040; PubMed Central PMCID: PMC2040456.

15. Sykora P, Yang JL, Ferrarelli LK, Tian J, Tadokoro T, Kulkarni A, et al. Modulation of DNA base excision repair during neuronal differentiation. Neurobiol Aging. 2013;34(7):1717–27. doi: 10.1016/j.neurobiolaging.2012.12.016 23375654; PubMed Central PMCID: PMC5576894.

16. Sultana R, Abdel-Fatah T, Abbotts R, Hawkes C, Albarakati N, Seedhouse C, et al. Targeting XRCC1 deficiency in breast cancer for personalized therapy. Cancer Res. 2013;73(5):1621–34. doi: 10.1158/0008-5472.CAN-12-2929 23253910.

17. De Summa S, Pinto R, Pilato B, Sambiasi D, Porcelli L, Guida G, et al. Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer. Cell Death Dis. 2014;5:e1076. doi: 10.1038/cddis.2014.30 24556691; PubMed Central PMCID: PMC3944247.

18. Ali R, Al-Kawaz A, Toss MS, Green AR, Miligy IM, Mesquita KA, et al. Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention. Cancer Res. 2018;78(24):6818–27. doi: 10.1158/0008-5472.CAN-18-0633 30297533.

19. Albarakati N, Abdel-Fatah TM, Doherty R, Russell R, Agarwal D, Moseley P, et al. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy. Mol Oncol. 2015;9(1):204–17. doi: 10.1016/j.molonc.2014.08.001 25205036; PubMed Central PMCID: PMC5528668.

20. Horton JK, Wilson SH. Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced Cytotoxicity. Front Oncol. 2013;3:257. doi: 10.3389/fonc.2013.00257 24137565; PubMed Central PMCID: PMC3786324.

21. Horton JK, Stefanick DF, Prasad R, Gassman NR, Kedar PS, Wilson SH. Base excision repair defects invoke hypersensitivity to PARP inhibition. Mol Cancer Res. 2014;12(8):1128–39. doi: 10.1158/1541-7786.MCR-13-0502 24770870; PubMed Central PMCID: PMC4135006.

22. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10(8):789–99. doi: 10.1038/nm1087 15286780.

23. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017;19(8):649–58. doi: 10.1016/j.neo.2017.05.002 28732212; PubMed Central PMCID: PMC5516091.

24. Sonavane M, Sykora P, Andrews JF, Sobol RW, Gassman NR. Camptothecin Efficacy to Poison Top1 Is Altered by Bisphenol A in Mouse Embryonic Fibroblasts. Chem Res Toxicol. 2018;31(6):510–9. doi: 10.1021/acs.chemrestox.8b00050 29799191.

25. Kirby TW, Gassman NR, Smith CE, Pedersen LC, Gabel SA, Sobhany M, et al. Nuclear Localization of the DNA Repair Scaffold XRCC1: Uncovering the Functional Role of a Bipartite NLS. Sci Rep. 2015;5:13405. doi: 10.1038/srep13405 26304019; PubMed Central PMCID: PMC4548243.

26. Kirby TW, Gassman NR, Smith CE, Zhao ML, Horton JK, Wilson SH, et al. DNA polymerase beta contains a functional nuclear localization signal at its N-terminus. Nucleic Acids Res. 2017;45(4):1958–70. doi: 10.1093/nar/gkw1257 27956495; PubMed Central PMCID: PMC5389473.

27. Holton NW, Ebenstein Y, Gassman NR. Broad spectrum detection of DNA damage by Repair Assisted Damage Detection (RADD). DNA Repair (Amst). 2018;66–67:42–9. doi: 10.1016/j.dnarep.2018.04.007 29723708.

28. Gassman NR, Wilson SH. Micro-irradiation tools to visualize base excision repair and single-strand break repair. DNA Repair (Amst). 2015;31:52–63. doi: 10.1016/j.dnarep.2015.05.001 25996408; PubMed Central PMCID: PMC4458156.

29. Holton NW, Andrews JF, Gassman NR. Application of Laser Micro-irradiation for Examination of Single and Double Strand Break Repair in Mammalian Cells. J Vis Exp. 2017;(127). doi: 10.3791/56265 28930988; PubMed Central PMCID: PMC5752190.

30. Chaim IA, Nagel ZD, Jordan JJ, Mazzucato P, Ngo LP, Samson LD. In vivo measurements of interindividual differences in DNA glycosylases and APE1 activities. Proc Natl Acad Sci U S A. 2017;114(48):E10379–E88. doi: 10.1073/pnas.1712032114 29122935; PubMed Central PMCID: PMC5715766.

31. Nagel ZD, Margulies CM, Chaim IA, McRee SK, Mazzucato P, Ahmad A, et al. Multiplexed DNA repair assays for multiple lesions and multiple doses via transcription inhibition and transcriptional mutagenesis. Proc Natl Acad Sci U S A. 2014;111(18):E1823–32. doi: 10.1073/pnas.1401182111 24757057; PubMed Central PMCID: PMC4020053.

32. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 2010;70(20):7970–80. doi: 10.1158/0008-5472.CAN-09-4521 20798217; PubMed Central PMCID: PMC2955854.

33. Chavez KJ, Garimella SV, Lipkowitz S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis. 2010;32(1–2):35–48. doi: 10.3233/BD-2010-0307 21778573; PubMed Central PMCID: PMC3532890.

34. Boichuk S, Galembikova A, Sitenkov A, Khusnutdinov R, Dunaev P, Valeeva E, et al. Establishment and characterization of a triple negative basal-like breast cancer cell line with multi-drug resistance. Oncol Lett. 2017;14(4):5039–45. doi: 10.3892/ol.2017.6795 29085518; PubMed Central PMCID: PMC5649570.

35. Hui L, Zheng Y, Yan Y, Bargonetti J, Foster DA. Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene. 2006;25(55):7305–10. doi: 10.1038/sj.onc.1209735 16785993.

36. Lim LY, Vidnovic N, Ellisen LW, Leong CO. Mutant p53 mediates survival of breast cancer cells. Br J Cancer. 2009;101(9):1606–12. doi: 10.1038/sj.bjc.6605335 19773755; PubMed Central PMCID: PMC2778523.

37. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989;342(6250):705–8. doi: 10.1038/342705a0 2531845.

38. Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, et al. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat. 2010;121(1):53–64. doi: 10.1007/s10549-009-0460-8 19593635.

39. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997;57(19):4285–300. 9331090.

40. Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer. 1998;78(6):766–74. doi: 10.1002/(sici)1097-0215(19981209)78:6<766::aid-ijc15>3.0.co;2-l 9833771.

41. Prasad R, Caglayan M, Dai DP, Nadalutti CA, Zhao ML, Gassman NR, et al. DNA polymerase beta: A missing link of the base excision repair machinery in mammalian mitochondria. DNA Repair (Amst). 2017;60:77–88. doi: 10.1016/j.dnarep.2017.10.011 29100041.

42. Gassman NR, Stefanick DF, Kedar PS, Horton JK, Wilson SH. Hyperactivation of PARP triggers nonhomologous end-joining in repair-deficient mouse fibroblasts. PLoS One. 2012;7(11):e49301. doi: 10.1371/journal.pone.0049301 23145148; PubMed Central PMCID: PMC3492265.

43. Horton JK, Stefanick DF, Gassman NR, Williams JG, Gabel SA, Cuneo MJ, et al. Preventing oxidation of cellular XRCC1 affects PARP-mediated DNA damage responses. DNA Repair (Amst). 2013;12(9):774–85. doi: 10.1016/j.dnarep.2013.06.004 23871146; PubMed Central PMCID: PMC3924596.

44. Slyskova J, Sabatella M, Ribeiro-Silva C, Stok C, Theil AF, Vermeulen W, et al. Base and nucleotide excision repair facilitate resolution of platinum drugs-induced transcription blockage. Nucleic Acids Res. 2018;46(18):9537–49. doi: 10.1093/nar/gky764 30137419; PubMed Central PMCID: PMC6182164.

45. Sawant A, Floyd AM, Dangeti M, Lei W, Sobol RW, Patrick SM. Differential role of base excision repair proteins in mediating cisplatin cytotoxicity. DNA Repair (Amst). 2017;51:46–59. doi: 10.1016/j.dnarep.2017.01.002 28110804; PubMed Central PMCID: PMC5328804.

46. Prasad R, Horton JK, Dai DP, Wilson SH. Repair pathway for PARP-1 DNA-protein crosslinks. DNA Repair (Amst). 2018. doi: 10.1016/j.dnarep.2018.11.004 30466837.

47. Kang YJ, Yan CT. Regulation of DNA repair in the absence of classical non-homologous end joining. DNA Repair (Amst). 2018;68:34–40. doi: 10.1016/j.dnarep.2018.06.001 29929045.

48. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67. doi: 10.1172/JCI45014 21633166; PubMed Central PMCID: PMC3127435.

49. Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41(Database issue):D955–61. doi: 10.1093/nar/gks1111 23180760; PubMed Central PMCID: PMC3531057.

50. Pommier Y, O'Connor MJ, de Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med. 2016;8(362):362ps17. doi: 10.1126/scitranslmed.aaf9246 27797957.

51. Gassman NR, Coskun E, Stefanick DF, Horton JK, Jaruga P, Dizdaroglu M, et al. Bisphenol a promotes cell survival following oxidative DNA damage in mouse fibroblasts. PLoS One. 2015;10(2):e0118819. doi: 10.1371/journal.pone.0118819 25693136; PubMed Central PMCID: PMC4334494.

52. Whitaker A, Schaich M, Smith M, Flynn T, Freudenthal B. Base excision repair of oxidative DNA damage: from mechanism to disease. Front Biosci (Landmark Ed). 2017;22:1493–522. PubMed Central PMCID: PMC5567671.

53. Horton JK, Watson M, Stefanick DF, Shaughnessy DT, Taylor JA, Wilson SH. XRCC1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaks. Cell Res. 2008;18(1):48–63. doi: 10.1038/cr.2008.7 18166976; PubMed Central PMCID: PMC2366203.

54. Uhlen M, Zhang C, Lee S, Sjostedt E, Fagerberg L, Bidkhori G, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357(6352). doi: 10.1126/science.aan2507 28818916.

55. Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia J, de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol. 1998;18(6):3563–71. doi: 10.1128/mcb.18.6.3563 9584196; PubMed Central PMCID: PMC108937.

56. Kiriyama T, Hirano M, Asai H, Ikeda M, Furiya Y, Ueno S. Restoration of nuclear-import failure caused by triple A syndrome and oxidative stress. Biochem Biophys Res Commun. 2008;374(4):631–4. doi: 10.1016/j.bbrc.2008.07.088 18662670.

57. Lakshmipathy U, Campbell C. Mitochondrial DNA ligase III function is independent of Xrcc1. Nucleic Acids Res. 2000;28(20):3880–6. doi: 10.1093/nar/28.20.3880 11024166

58. Gao Y, Katyal S, Lee Y, Zhao J, Rehg JE, Russell HR, et al. DNA ligase III is critical for mtDNA integrity but not Xrcc1-mediated nuclear DNA repair. Nature. 2011;471(7337):240–4. doi: 10.1038/nature09773 21390131; PubMed Central PMCID: PMC3079429.

59. Takanami T, Nakamura J, Kubota Y, Horiuchi S. The Arg280His polymorphism in X-ray repair cross-complementing gene 1 impairs DNA repair ability. Mutat Res. 2005;582(1–2):135–45. doi: 10.1016/j.mrgentox.2005.01.007 15781218.

60. Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2019;47(D1):D941–D7. doi: 10.1093/nar/gky1015 30371878; PubMed Central PMCID: PMC6323903.

61. Parsons JL, Tait PS, Finch D, Dianova II, Allinson SL, Dianov GL. CHIP-mediated degradation and DNA damage-dependent stabilization regulate base excision repair proteins. Mol Cell. 2008;29(4):477–87. doi: 10.1016/j.molcel.2007.12.027 18313385.

62. Fang Q, Inanc B, Schamus S, Wang XH, Wei L, Brown AR, et al. HSP90 regulates DNA repair via the interaction between XRCC1 and DNA polymerase beta. Nat Commun. 2014;5:5513. doi: 10.1038/ncomms6513 25423885; PubMed Central PMCID: PMC4246423.

63. Braithwaite EK, Kedar PS, Lan L, Polosina YY, Asagoshi K, Poltoratsky VP, et al. DNA polymerase lambda protects mouse fibroblasts against oxidative DNA damage and is recruited to sites of DNA damage/repair. J Biol Chem. 2005;280(36):31641–7. doi: 10.1074/jbc.C500256200 16002405.

64. Braithwaite EK, Prasad R, Shock DD, Hou EW, Beard WA, Wilson SH. DNA polymerase lambda mediates a back-up base excision repair activity in extracts of mouse embryonic fibroblasts. J Biol Chem. 2005;280(18):18469–75. doi: 10.1074/jbc.M411864200 15749700.

65. Polo LM, Xu Y, Hornyak P, Garces F, Zeng Z, Hailstone R, et al. Efficient Single-Strand Break Repair Requires Binding to Both Poly(ADP-Ribose) and DNA by the Central BRCT Domain of XRCC1. Cell Rep. 2019;26(3):573–81 e5. doi: 10.1016/j.celrep.2018.12.082 30650352; PubMed Central PMCID: PMC6334254.

66. Camirand A, Fadhil I, Luco AL, Ochietti B, Kremer RB. Enhancement of taxol, doxorubicin and zoledronate anti-proliferation action on triple-negative breast cancer cells by a PTHrP blocking monoclonal antibody. Am J Cancer Res. 2013;3(5):500–8. 24224127; PubMed Central PMCID: PMC3816969.

Defective base excision repair in the response to DNA damaging agents in triple negative breast cancer

Souhrn

Klíčová slova:

Zdroje

PLOS One

Svět praktické medicíny 1/2024 (znalostní test z časopisu)

Koncepce osteologické péče pro gynekology a praktické lékaře

Sekvenční léčba schizofrenie

Hypertenze a hypercholesterolémie – synergický efekt léčby

Význam metforminu pro „udržitelnou“ terapii diabetu